• Highly regarded consumer App marketing and growth specialist, Sasha Grant, appointed as Head of Growth for PainChek Infant App
• PainChek Infant App is regulatory cleared as a pain assessment tool for infants in multiple markets
• Total Addressable Market (TAM) for the PainChek Infant App of circa A$15 Billion per annum

PainChek Ltd has announced the appointment of Sasha Grant as Head of Growth for the PainChek Infant App. Sasha is an experienced business leader in Direct-to-Consumer Apps and online technology, having worked with significant global brands including Expedia Group, WikiCamps App (GDAY Group), and EBAY. In her previous role as product leader for the hugely successful WikiCamps App, Australia's number 1 paid app in the Apple app store, Sasha commercialized and re-platformed the App that now has a community of over 1.5m users. The PainChek Infant App has been approved by the Australian and European regulatory authorities as a pain assessment tool for infants aged 1 month to 12 months. There are 400 million preverbal children globally and 150 million babies are born each year, and to date PainChek Infant is the only validated and regulated pain assessment tool for this vulnerable group. The Infant market alone has a potential indicative value of up to $15Bn AUD per annum. The Company has completed technical and logistic issues to successfully launch the Infant App on both the Apple Store and Google Play store in Australia as part of the initial direct-to-consumer market strategy. The Company is now focused on refining the product pricing and promotional campaign, redesigning the website, improving the self-registration flow, and expanding marketing efforts. The goal is to replicate the success of the PainChek Adult App and commercialize the PainChek Infant technology globally, both for the direct-to-parent and healthcare professional segments.

The core forward-looking strategies include: continuing to broaden the direct-to-parent marketing and expand subscriptions across Australia; expanding direct-to-consumer access via App Store and Google Play store to new international markets including the UK, Canada, and broader European markets; and following up with the FDA to commence the PainChek Infant App for US market regulatory clearance process.